Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
Saved in:
| Title: | Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. |
|---|---|
| Authors: | Stover EH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Oh C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Keskula P; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Tseng YY; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Adalsteinsson VA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Lohr JG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Thorner AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ducar M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kryukov GV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Ha G; Public Health Sciences Division and Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Rosenberg M; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Internal Medicine Program, Legacy Health, Portland, Oregon, USA., Freeman SS; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, USA., Wu X; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Takeda DY; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Loda M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.; Department of Pathology and Laboratory Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA., Wu CL; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA., Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Garraway LA; Genentech/Roche, San Francisco, California, USA., Boehm JS; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Huang FW; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.; Division of Hematology and Oncology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA. |
| Source: | The Prostate [Prostate] 2022 Apr; Vol. 82 (5), pp. 584-597. Date of Electronic Publication: 2022 Jan 27. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0045 |
|---|---|
| DOI: | 10.1002/pros.24305 |
